West Pharmaceutical Services (WST)

Total return at 5 years: -3.1%/year = -3.4% appreciation + 0.3% dividend. The target price ($309) is ex-dividend; the $5 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $195 · Multiples $252) is below the market price ($368).

Today — expensive, no margin of safety: at $368 trades ~45.6% above its value discounted to today (~$252); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$157.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($368) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The price discounts growth (24.1%/year) above our base case (8.5%/year) → it is priced for a demanding scenario and leaves little cushion against a slowdown.

That growth implies ~$1.3 bn of owner earnings in year 5 (vs ~$0.6 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 = TTM to 30-Jun-2026 (US$3,326.8M of revenue). Year 1 anchors to the two anchors of the guidance in the Q2-2026 results 8-K (23-Jul-2026, raised): reported revenue +8.8/+10.0% (midpoint +9.4%) and adjusted diluted earnings per share of US$8.85-9.05 (midpoint US$8.95), which on guided revenue implies a normalized net margin of ~18.8% — well above the rolling GAAP margin (~17.0%) because it excludes restructuring, the SmartDose divestiture and an investment impairment (US$36.2M pre-tax in 2025). From that start, revenue decelerates smoothly toward ~7.7% by year 5 (geometric decay, without jumps) and the net margin keeps expanding modestly toward ~20.0% on the mix shift toward high-value components (HVP Components/Delivery Devices, growing +19-30% in Q2-2026) and the exit from SmartDose (lower margin). The operating and cash margins follow the same modest expansion, supported by capex growing more slowly than revenue (FY2026 guidance US$250-275M, unchanged, against revenue rising ~9%). Exit multiple within the band of the regulated medical components specialist (16-22× on after-tax operating income): base ~20× (regulatory moat + return on capital ~19.7% versus the 10% bar), compressing to 16× in the bear case (pricing pressure / migration to oral formulations) and expanding to 22× in the bull case (acceleration in biologics/GLP-1). Buybacks were material and accelerated sharply in 2026 (US$454.3M in the first half under the program announced in Feb-2026, versus US$134.0M in all of 2025): they are modeled with a share path starting from the current 71.3M diluted shares, at a moderate net pace (the first-half peak is not extrapolated) funded with free cash flow, without accumulating cash (the surplus goes to buybacks).

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $309 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $368, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $309 in 5 years plus $5 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $252. Against the current market price ($368), the margin of safety is -45.6% (trades above the maximum → a premium is paid) and the total return at that price would be -3.1% annually.

• Multiple vs quality. EV/NOPAT 48× — well above reference band of 16-22× for the category, for normalized growth that converges to ~20.0% net margin by year 5.
• Reverse-DCF. Market price demands sustained growth above the favorable scenario to justify a 10% return.
• Margin of safety. No margin of safety: the price already discounts a demanding scenario. Total return -3% falls far short of compensating for risk at this price.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (95%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC exceeds cost of capital. Return on capital 19.7% vs the 10% bar → solid value creation.
• Margin and stability. Adjusted operating margin ~22.6% in most recent quarter and expanding from mix to high-value components.
• Cash quality. Reported free cash flow converges with operating cash flow less capex; expansion capex decelerates relative to revenues as installed capacity matures.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The Proprietary Products driver is volume of injectable drugs approved with West components × content of West components per dose, which rises when the customer migrates from a simple stopper to a complete auto-injection system (HVP Delivery Devices). The West Vantage driver is volume of devices assembled by contract, currently driven by auto-injection devices for obesity/diabetes and pressured by decline in diagnostic devices.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. Growth is mostly organic (FY2026 guidance: organic +10.0/+11.0%, with ~1 percentage point FX tailwind).
• Growth engine. Biologics and elastomers for GLP-1 treatments, plus mix to high-value components (HVP Components/Delivery Devices).
• Deceleration and cycle. Q3-2026 revenue guidance shows marked reported deceleration (from tough comparatives and SmartDose exit) that does not reflect a change in structural trend.

• Relevant in 10 years (recurrence). Approved injectable drugs keep using the same components for the product's entire life — high and predictable recurrence.
• Pricing power. Regulatory moat sustains price in Proprietary Products, but West Vantage faces direct cost pressure from regional competitors and CMOs.
• Moat and its direction. Narrow but real regulatory moat and stable; reinforces with each new approval using West components.
• Capital cycle. Sector with high regulatory entry barriers, but with established competitors (Datwyler, Aptar) and cost pressure in contract manufacturing segment.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)1360.0x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 95% of ROIC
• ✓Value creation (ROIC − 10% bar)+10pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 1.2x
• !Float / working capitalConsumes cash $0.1 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.0% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Positive net cash ($435.8M vs debt $202.9M); leverage immaterial.
• Coverage and cash. Net interest income (more interest income than expense); coverage is not a risk topic for this company.
• Pending litigation. Shareholder class action (New England Teamsters Pension Fund) in progress since May-2025, with no estimated loss disclosed to date.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. Dominant passive institutional ownership (Vanguard + BlackRock ~22%); with no controlling shareholder nor insider ownership detail available in proxy.
• Capital allocation. Aggressive buyback in 2026 ($454.3M in the half) under new program; no material M&A recently, the only corporate transaction was SmartDose divestment.
• Integrity / normalization. One-offs (restructuring, SmartDose sale, investment impairment) clearly declared in the non-GAAP reconciliation in the earnings release.

• No identifiable source of discount: West trades at a multiple well above its category band, sustained by guided acceleration in biologics and GLP-1.
• The market pays a premium for the combination of regulatory moat, solid ROIC (19.7%), and a structural tailwind that the company itself raised guidance on this quarter.
• Known risks (shift to oral formulations, customer concentration, Daikyo license) are already in the public narrative, but the price leaves no margin if any materialize.

No missing buyers or motivated sellers → not cheap; a real-quality business at a price that already incorporates several years of guided acceleration. The total return (-3%) stays well below what the verdict itself demands.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -11%/year (-43% total): the margin of safety protects the downside. The bull (+1%/year, +4% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Shift to oral formulations. The structural long-term disconfirmer: if GLP-1 and other treatments migrate from injectable to oral, demand for injectable packaging shrinks.
• Multiple above band. 48× vs 16-22× reference — multiple compression if guided growth disappoints.
• Customer concentration. Top customer represents 15.8% of sales ($485.9M); top ten, 47.6%.
• Daikyo license dependence. Key proprietary technology exclusively licensed, with agreement in force through 2027.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A narrow moat and ROIC 20% above the 10% bar, but the price sits above value (no margin) → great business, expensive.

• Peter Lynch Growth at a reasonable price (GARP)

  A fast grower growing 9% at a multiple/growth of 5.6 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 3% (EBIT/EV) + ROIC 20% → falls outside the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 24% vs our 9%: priced for perfection, no favorable mispricing.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -11%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, stable; sources: intangibles, efficient scale, switching costs → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  The price demands 24% growth, far above our 9% — heroic assumptions.